NeuroPace Inc (NPCE) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
NPCE currently has 33.1M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 17.88% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 04, 2025 |
10-Q filing | 33.1M shares outstanding |
33M | 0 |
| May 13, 2025 |
10-Q filing | 31.5M shares outstanding |
31M | 0 |
| Mar 04, 2025 |
10-K filing | 32.6M shares outstanding |
33M | 0 |
| Nov 12, 2024 |
10-Q filing | 29.4M shares outstanding |
29M | 0 |
| Aug 13, 2024 |
10-Q filing | 28.9M shares outstanding |
29M | 0 |
| May 08, 2024 |
10-Q filing | 28.3M shares outstanding |
28M | 0 |
| Mar 05, 2024 |
10-K filing | 25.9M shares outstanding |
26M | 0 |
| Nov 06, 2023 |
10-Q filing | 26.0M shares outstanding |
26M | 0 |
| Aug 08, 2023 |
10-Q filing | 25.5M shares outstanding |
25M | 0 |
| May 04, 2023 |
10-Q filing | 25.1M shares outstanding |
25M | 0 |
| Mar 02, 2023 |
10-K filing | 24.6M shares outstanding |
25M | 0 |
| Nov 08, 2022 |
S-3 filing: NeuroPace, Inc. files an S-3 registration statement to offer and sell up to $150,000,000 of any combination of common stock, preferred stock, and debt securities. |
25M | 0 |
| Nov 08, 2022 |
10-Q filing | 24.7M shares outstanding |
25M | 0 |
| Aug 11, 2022 |
10-Q filing | 24.5M shares outstanding |
25M | 0 |
| May 12, 2022 |
10-Q filing | 24.3M shares outstanding |
24M | 0 |
| Mar 10, 2022 |
10-K filing | 24.5M shares outstanding |
24M | 0 |
| Nov 10, 2021 |
10-Q filing | 24.1M shares outstanding |
24M | 0 |
| Aug 12, 2021 |
10-Q filing | 24.3M shares outstanding |
24M | 0 |
| Jun 03, 2021 |
10-Q filing | 24.3M shares outstanding |
24M | 0 |
| Apr 21, 2021 |
POS AM filing: This POS AM filing is for an offering of common stock, with the company offering 5,313,000 shares and granting underwriters an option to purchase an additional 796,950 shares. The company intends to use the net proceeds to expand sales and marketing efforts, increase research and development activities, conduct or sponsor clinical studies, expand internationally, repay debt, and for working capital and other general corporate purposes. |
17M | 0 |
| Apr 14, 2021 |
S-1/A filing: This S-1/A filing outlines an offering of common stock with the primary purpose of raising additional capital for sales and marketing, research and development, clinical studies, international expansion, working capital, and general corporate purposes, as well as repaying approximately $4.0 million of principal indebtedness. |
22M | 6.1M |
| Mar 24, 2021 |
S-1 filing: S-1 filing for an IPO to raise capital, expand sales and marketing, increase research and development activities, conduct clinical studies, expand internationally, provide working capital, repay $4.0 million of indebtedness under the Paycheck Protection Program loan, and acquire complementary products, technologies, intellectual property or businesses. |
44M | 0 |